Alpha Cognition Inc.
ACOG · Nasdaq · Canada / United States
Share price · ACOG
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ACOG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+8.6%
Nothing announced by ACOG that day or the session before.
- 20 Aug 2026+6.9%
Nothing announced by ACOG that day or the session before.
- 27 Jul 2026+8.6%
Nothing announced by ACOG that day or the session before.
- 21 Jul 2026-5.4%
Nothing announced by ACOG that day or the session before.
- 1 Jul 2026+7.9%
Nothing announced by ACOG that day or the session before.
- 17 Jun 2026+11.1%
Nothing announced by ACOG that day or the session before.
- 15 May 2026+6.0%
- 12 May 2026-7.7%
Nothing announced by ACOG that day or the session before.
- 7 Apr 2026+12.3%
Nothing announced by ACOG that day or the session before.
- 18 Feb 2026+11.3%
Nothing announced by ACOG that day or the session before.
Share of unusual movement by asset
For each asset, the share of ACOG's own-move activity since 13 Nov 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Benzgalantamine(Zunveyl) | Approved | Acetylcholinesterase/nicotinic receptor (prodrug)Small molecule | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $7.8M | $1.3M | $38M | $7.6M-$4.8M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $6.1M | $2.0M | $41M | $8.8M-$6.9M operating cash flow | report ↗ |
| 2026-Q1 | $3.5M | $1.1M | $54M | $6.5M-$12M operating cash flow | report ↗ |
| 2025-Q3 | $2.8M | $0.6M | $35M | $1.3M-$5.3M operating cash flow | report ↗ |
| 2025-Q2 | $1.7M | $0.3M | $39M | $10M-$6.1M operating cash flow | report ↗ |
| 2025-Q1 | $2.9M | $0.4M | $46M | $2.0M-$2.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.0M | $3.8M | $1.9M-$1.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.0M | $1.2M | $2.1M-$1.4M operating cash flow | report ↗ |
| 2024-Q1 | — | $0.9M | $2.4M | $5.0M-$2.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.4M | $0.9M | $3.3M-$1.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.3M | $1.2M | $2.8M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $10M | $1.9M | $66M | $5.2M-$20M operating cash flow | report ↗ |
Alpha Cognition reported fiscal 2025 total revenue of $10.22M, consisting of $6.8M in ZUNVEYL net product revenue and $3.4M in licensing revenue. R&D spend was $1.87M, down 52.3% YoY from $3.92M, and cash and cash equivalents totaled $66.11M at year-end. The company reported a net loss of $20.67M, with quarterly net burn of $20.67M.
Management reiterated its target of operating profitability in 2027 and expects approximately two years of cash runway at forecasted operating levels. The company executed a second national PBM contract, bringing it to two of four major PBMs relevant to long-term care, and fourth-quarter bottles dispensed rose 62% QoQ to 4,941, with December the strongest month since launch. Operational highlights include ongoing enrollment in the BEACON study, planned initiation of the CONVERGE and RESOLVE studies, planned advancement of a sublingual formulation into the clinic in 2026, expected ex-US approvals via partner CMS in Asia, and issuance of an additional U.S. patent covering ZUNVEYL dosing regimens.
Insider transactions
Open-market activity, trailing 12 months: 60 purchases ($8.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | Deardorf Caren · director | Award / grant | 755 | — | — | Form 4 |
| 2026-11-11 | Deardorf Caren · director | Award / grant (derivative) | 1,020 | — | — | Form 4 |
| 2026-10-23 | Opaleye Management Inc. · 10% owner | Open-market purchase | 14,973 | $8.23 | $123K | Form 4 |
| 2026-10-22 | Opaleye Management Inc. · 10% owner | Open-market purchase | 17,117 | $8.33 | $143K | Form 4 |
| 2026-10-16 | Opaleye Management Inc. · 10% owner | Open-market purchase | 14,283 | $8.23 | $118K | Form 4 |
| 2026-10-15 | Opaleye Management Inc. · 10% owner | Open-market purchase | 22,657 | $8.43 | $191K | Form 4 |
| 2026-10-01 | Opaleye Management Inc. · 10% owner | Open-market purchase | 19,050 | $8.69 | $166K | Form 4 |
| 2026-09-25 | Opaleye Management Inc. · 10% owner | Open-market purchase | 13,426 | $8.47 | $114K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 24 reporting institutions held 10.5M shares ($57.7M, 48.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Opaleye Management Inc. | 2,561,950 | $14.1M |
| 2 | Solas Capital Management, LLC | 1,924,617 | $10.6M |
| 3 | AWM Investment Company, Inc. | 1,672,168 | $9.2M |
| 4 | Cable Car Capital, LP | 1,382,339 | $7.6M |
| 5 | Ikarian Capital, LLC | 1,056,259 | $5.8M |
| 6 | SPHERA FUNDS MANAGEMENT LTD. | 567,616 | $3.1M |
| 7 | Alyeska Investment Group, L.P. | 365,000 | $2.0M |
| 8 | BOOTHBAY FUND MANAGEMENT, LLC | 256,393 | $1.4M |
| 9 | Aristides Capital LLC | 218,510 | $1.2M |
| 10 | CANTOR FITZGERALD, L. P. | 188,631 | $1.0M |
| 11 | CITADEL ADVISORS LLC | 89,589 | $492K |
| 12 | VILLERE ST DENIS J & CO LLC | 71,158 | $391K |
| 13 | TUDOR INVESTMENT CORP ET AL | 61,596 | $338K |
| 14 | ACT CAPITAL MANAGEMENT, LLC | 51,500 | $283K |
| 15 | TWO SIGMA INVESTMENTS, LP | 15,886 | $87K |